RETRACTED: Tumor dependence on the EGFR signaling pathway expressed by the p-EGFR:p-AKT ratio predicts erlotinib sensitivity in human non-small cell lung cancer (NSCLC) cells expressing wild-type EGFR gene.
The Journal of Thoracic Oncology was alerted on August 16, 2021 that Figures 1 and 3 in this article are suspected of image manipulation. The editorial team promptly consulted with the authors and publisher. The authors stand by the validity of the conclusions and the scientific merit of the manuscript but acknowledge that some Figures might not have been properly prepared. Therefore, the editorial team asserts that the conclusions could be unreliable.
Li
Tianhong
T
Department of Oncology, Montefiore Medical Center and the Albert Einstein Cancer Center, Bronx, NY 10461, USA. tli@montefiore.org
Ling
Yi-He
YH
Perez-Soler
Roman
R
D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy / Q000235:genetics* / Q000473:pathology; D045744:Cell Line, Tumor; D004273:DNA, Neoplasm / Q000235:genetics; D004305:Dose-Response Relationship, Drug; D066246:ErbB Receptors / Q000037:antagonists & inhibitors / Q000096:biosynthesis* / Q000235:genetics; D000069347:Erlotinib Hydrochloride; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects*; D018773:Genes, erbB-1 / Q000235:genetics*; D006801:Humans; D015151:Immunoblotting; D008175:Lung Neoplasms / Q000188:drug therapy / Q000235:genetics* / Q000473:pathology; D009154:Mutation; D019869:Phosphatidylinositol 3-Kinases / Q000096:biosynthesis* / Q000235:genetics; D010766:Phosphorylation; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage; D011799:Quinazolines / Q000008:administration & dosage*; D015398:Signal Transduction / Q000187:drug effects
D004273:DNA, Neoplasm; D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D000069347:Erlotinib Hydrochloride; D019869:Phosphatidylinositol 3-Kinases; D066246:ErbB Receptors